Skip to Main Content

Despite giddy advances in treating cancer, a new analysis finds needed medicines have been reaching patients in the U.K. more slowly, and that both drug makers and government agencies are to blame.

After reviewing 97 cancer drugs authorized by the European Medicines Agency from 2000 to 2016, the researchers found that drug makers generated an insufficient number of new treatments for cancers with the highest unmet medical need and that clinical trials took longer before regulatory approval was sought, according to the analysis published in Drug Discovery Today.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!